Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ALNY stock hub

ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

Read full analysis Valuation Archive

Fair value midpoint

$666

$388 - $975

Upside to midpoint

+128.0%

Based on latest report

Confidence

86/100

Data quality and model convergence

Market cap

$39.0B

NASDAQ

Our take

Research highlights

What our analysis says

Pulled from the latest published report. The full reasoning lives under /analysis.

Biggest opportunity

Bull case

The market is pricing ALNY as a mature rare-disease biotech rather than an inflecting hyper-growth platform.

Biggest risk

Prevalent Disease Pipeline Failure

12-24 months

Recommended action

Strong Buy

ALNY is rated Strong Buy at $292.03 versus the reconciled fair value midpoint of $665.75, implying +127.97% upside/downside. Confidence is separately disclosed at 86/100.

Market data

Live price

Current market quote for this ticker.

Current price

ALNY

In the news

Latest news · ALNY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Analysis map

Jump into the research surface

These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.

Forecast

Targets

Bull, base, and bear cases with expected-return framing.

Valuation

Models

Fair-value bridge, DCF, owner earnings, and peer multiples.

Sensitivity

Grid

Cost-of-equity and terminal-growth stress table.

Risks

Bear case

Kill scenarios, soft-pass flags, and downside catalysts.

Earnings

Decision tree

Next earnings setup and beat / inline / miss thresholds.

Position sizing

Checkpoints

Entry, exit, conviction, and quarterly monitoring rules.

Financials

History

Revenue, margins, cash flow, and balance-sheet context.

Peers

Comps

Relative valuation and profitability against the cohort.

Moat

Durability

Economic-profit evidence and competitive advantage risk.

Industry cycle

Context

Sector phase, capital cycle, and secular tailwinds.

Scorecard

Factors

Six-factor overlay and 9-category weighted scorecard.

Recommendation

Verdict

Final action, action steps, opportunity, and biggest risk.

Perspectives

Lenses

Growth, value, and income investor reads.

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E21

P25 12.3P50 18.4P75 33.1

Trailing P/E0

P25 14.9P50 23.2P75 38.5

ROE90.4

P25 -105.6P50 -46.5P75 -3.1

ROIC78.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Our take

Indicator catalog

All ALNY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

241

Groups with data

Currency

USD

Showing 241 of 241 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001178670
Company name	Alnylam Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	02043Q107
Employees	2,500
Employees Change	270%
Employees Change Percent	12.11
Enterprise value	$39.4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
In Index	NASDAQ100
Industry	Biotechnology
IPO Date	2004-05-28
Isin	US02043Q1076
Last refreshed	2026-05-10
Market cap	$39.4B
Market cap category	Large-Cap
Price	$295
Price currency	USD
Rev Per Employee	1,714,769.2x
Sector	Healthcare
Sic	2834
Symbol	ALNY
Website	https://www.alnylam.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.37%
EV Earnings	73.15x
EV Sales Forward	6.12x
EV/EBIT	52.32x
EV/EBITDA	48.77x
EV/FCF	61.17x
EV/Sales	9.18x
FCF yield	1.63%
Forward P/E	35.88x
P/B ratio	36.61x
P/E ratio	74.69x
P/S ratio	9.19x
PS Forward	6.12x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	17.54%
EBITDA Margin	18.82%
FCF margin	15.01%
Gross margin	80.83%
Gross Profit	$3.5B
Gross Profit Growth	71.56%
Gross Profit Growth Q	82.75%
Gross Profit Growth3 Y	53.64%
Gross Profit Growth5 Y	48.79%
Net Income	$538M
Net Income Growth Quarters	3%
Net Income Growth Years	3%
Pretax Margin	12.76%
Profit Margin	12.55%
Profit Per Employee	$215,196
Profitable Years	1
ROA	10.06
Roa5y	-5.39
ROCE	19.9
ROE	90.36
ROIC	78.43
Roic5y	-149.3

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	18.18%
Cagr15y	25.38%
Cagr1y	6.7%
Cagr20y	15.79%
Cagr3y	11.64%
Cagr5y	17.58%
EPS Growth Quarters	3
EPS Growth Years	3
Revenue Growth	82.57x
Revenue Growth Q	96.43x
Revenue Growth Quarters	6x
Revenue Growth Years	7x
Revenue Growth3 Y	55.35x
Revenue Growth5 Y	49.66x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.92
Assets	$5.1B
Cash	$3B
Current Assets	$4.2B
Current Liabilities	$1.3B
Debt	$3B
Debt EBITDA	$3.36
Debt Equity	$2.76
Debt FCF	$4.62
Equity	$1.1B
Interest Coverage	2.85
Liabilities	$4.1B
Long Term Assets	$910.2M
Long Term Liabilities	$2.7B
Net Cash	$39M
Net Cash By Market Cap	$0.1
Net Debt EBITDA	$-0.05
Net Debt Equity	$-0.04
Net Debt FCF	$-0.06
Tangible Book Value	$1.1B
Tangible Book Value Per Share	$8.06
WACC	6.11

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.13
Inventory Turnover	10.99
Net Working Capital	$133.8M
Quick ratio	2.88
Working Capital	$2.9B
Working Capital Turnover	$1.69

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-6.45%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	431.14%
1Y total return	6.69%
200-day SMA	392.3
3Y total return	39.14%
50-day SMA	316.4
50-day SMA vs 200-day SMA	50under200
5Y total return	124.71%
All Time High	495.6
All Time High Change	-40.46%
All Time High Date	2025-10-20
All Time Low	3.65
All Time Low Change	7,983.56%
All Time Low Date	2004-08-18
ATR	11.49
Beta	0.3
Beta1y	0.64
Beta2y	0.9
Ch YTD	-25.8
High	300.2
High52	495.6
High52 Date	2025-10-20
High52ch	-40.46%
Low	293.1
Low52	246
Low52 Date	2025-05-08
Low52ch	19.96%
Ma50ch	-6.74%
Price vs 200-day SMA	-24.79%
RSI	39.39
RSI Monthly	47.58
RSI Weekly	30.55
Sharpe ratio	0.25x
Sortino ratio	0.55
Total Return	-6.45%
Tr YTD	-25.8
Tr15y	2,874.29%
Tr1m	-7.66%
Tr1w	-0.36%
Tr3m	-10.09%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	28
Analyst Count Top	14
Analyst Price Target Top	$454
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$1.36
Earnings EPS Estimate Growth	369
Earnings Revenue Estimate	1,119,276,464x
Earnings Revenue Estimate Growth	88.37x
Operating Income	$752.1M
Operating Income Growth Q	1,386.1
Operating margin	17.54
Price target	$470
Price Target Change	$59.4
Price Target Change Top	$53.85

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	132,960,706%
Float Percent	99.59%
Net Borrowing	-546,946,000
Shares Insiders	0.37%
Shares Institutions	97%
Shares Out	133,512,573
Shares Qo Q	1.43%
Shares Yo Y	6.45%
Short Float	3.79%
Short Ratio	4.37
Short Shares	3.77

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$281.7M
Average Volume	1,142,276.65x
Bv Per Share	8.06
CAPEX	$-71.6M
Ch10y	431.1
Ch15y	2,874.3
Ch1m	-7.66
Ch1w	-0.36
Ch1y	6.69
Ch20y	1,778.1
Ch3m	-10.09
Ch3y	39.14
Ch5y	124.7
Ch6m	-33.35
Change	-0.29%
Change From Open	-0.29
Close	295.9
Days Gap	0
Depreciation Amortization	54,806,000
Dollar Volume	273,440,538
Earnings Date	2026-04-30
Earnings Time	bmo
EBIT	$752.1M
EBITDA	$806.9M
EPS	$3.95
F Score	6
FCF	$643.3M
FCF EV Yield	1.63x
FCF Per Share	$4.82
Financing CF	-335,558,000
Fiscal Year End	December
Founded	2,002
Graham Number	26.76254
Graham Upside	-90.93
Income Tax	$9.2M
Investing CF	297,018,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-12
Ma150	377.5
Ma150ch	-21.84%
Ma20	309.8
Ma20ch	-4.75%
Net CF	690,170,000
Next Earnings Date	2026-07-30
Open	295.9
Optionable	Yes
P FCF Ratio	61.23
P OCF Ratio	55.1
Position In Range	27.99
Post Close	295.1
Postmarket Change Percent	-0.51
Postmarket Price	$294
Ppne	707,556,000
Price Date	2026-05-08
Price EBITDA	$48.82
Ptbv Ratio	36.63
Relative Volume	0.81x
Revenue	4,286,923,000x
SBC By Revenue	8.44x
Share Based Comp	361,677,000
Tax By Revenue	0.21x
Tax Rate	1.68%
Tr20y	1,778.1%
Tr6m	-33.35%
Us State	Massachusetts
Volume	926,760
Z Score	7.37

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

9/10

Business quality stays separate from stock attractiveness.

Forward P/E

21.0x

Valuation uses the full report model stack, not a single multiple.

Next action

Strong Buy

Final action steps are kept in the recommendation tab.

Our take

Income

Does ALNY pay a dividend?

Capital-return profile for this ticker.

Performance

ALNY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ALNY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+97.0%

Float: +99.6% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ALNY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

39.4

Neutral momentum band

Price vs 200-day MA

-24.8%

50/200-day relationship not available

Beta (5Y)

0.30

Less volatile than the market

Sharpe ratio

0.25

Risk-adjusted return — higher is better; >1.0 is solid.

Peers

ALNY vs. sector cohort

Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ANET	Arista Networks Inc.	178.5B	48.7x	18.4x	237.4%	+31.6%	+64.0%	मज़बूत ख़रीद
DDOG	Datadog Inc.	71.2B	525.2x	19.4x	-3.7%	+40.5%	+88.8%	बेचें
LLY	Eli Lilly and Company	845.8B	33.7x	11.7x	41.9%	+23.2%	+23.0%	मज़बूत ख़रीद

Questions

About ALNY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ALNY stock rating?

Alnylam Pharmaceuticals, Inc. is currently shown with Strong Buy in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ALNY analysis?

The full report lives at /stocks/ALNY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ALNY?

The latest report frames ALNY around $388 to $975. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ALNY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.